In September, we added 95 citations in DIDB, including 50 in vitro (with 22 articles published in Sep 2026) and 45 in vivo articles (with 31 articles published in Sep 2026). Three NDAs and 1 BLA approved by the FDA from July to August in 2026, including centanafadine (SYMTRIYO), florquinitau F18 (TAUKLARIFY), iberdomide (ZENBEXUS), and garetosmab (PASATRU), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.